Immunosyn Corporation, a development stage company, owns a license to market, distribute, and sell a biopharmaceutical drug product for multiple uses worldwide. SF-1019 The company's biopharmaceutical drug product, SF-1019, is an experimental extract from caprine (goat) serum which it contains various peptides or lipopeptide molecules. SF-1019 would be used for the treatment of various diseases and pathological conditions, primarily consisting of chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, and diabetic ulcers. The license for SF-1019 has been granted to the company by Argyll Biotechnologies, LLC. The company also has rights to any improvement of SF-1019 and other compounds, which are developed using the same technology platform and which are chemically similar to SF-1019. History Immunosyn Corporation was founded in 2006.
(IMYN:OTC Pink - No Information)
10815 Rancho Bernardo Road
San Diego, CA 92127
|No competitor information is available for IMYN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- Pittsburgh, PA | Carnegie Museums of PittsburghPosted: Dec 09
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA | Mack-sumner CommunicationsPosted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
Sponsored Financial Commentaries
To contact IMMUNOSYN CORP, please visit www.immunosyn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.